Diazepam Trial in GAD65 Associated Epilepsy

Phase 1

Withdrawn

• Conditions: GAD 65 Antibody-associated Epilepsy
• Interventions: Drug: Diazepam

• Registration Number: NCT05361447
• Lead Sponsor: Mayo Clinic

Brief Summary

The purpose of this study is to determine whether diazepam reduces the frequency of seizures in GAD65 antibody associated epilepsy.

Detailed Description

GAD65 is an intracellular enzyme that plays a key role in the conversion of glutamate to gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the CNS. Benzodiazepines augment the sensitivity of the GABA-A receptor to GABA, prolonging its inhibitory effect, perhaps enhancing the potential for neural inhibition in conditions in which GABA is depleted.

GAD65 antibodies have been identified in a subset of patients with drug resistant focal epilepsy and limbic encephalitis. While it has not been definitively determined that these antibodies cause GAD65 inhibition and GABA depletion directly, diazepam, a common benzodiazepine, has been established as a mainstay of therapy for stiffperson's syndrome, a condition that is commonly associated with GAD65 antibody positivity. Given these observations, diazepam has been used by the investigators in a small number of patients with intractable epilepsy in the setting of GAD65 antibody positivity, with some encouraging anecdotal results with one patient being rendered seizure free for three years.

The purpose of this study is to generate prospective data on use of diazepam in patients with epilepsy related to high-titer GAD65 antibody positivity.

Study Timeline

• Study First Submitted: 2022-05-01
• Study First Submitted QC: 2022-05-01
• Study First Posted: 2022-05-04
• Study Start: 2023-01-11
• Primary Completion: 2024-12-13
• Study Completion: 2024-12-13
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-04
• Last Update Posted: 2025-03-06

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• High-titer serum GAD65 positivity > 20 nmol/L High-titer serum GAD65 IgG seropositivity titer >20 nmol/L and/or CSF GAD65 seropositivity titer > 0.02 nmol/L.
• Drug-resistant focal epilepsy, having failed 2 previous anti-seizure medications.
• Stable treatment for the 1 month prior to enrollment.
• Patients must be able to give informed consent or have an appropriate representative available to do.

Exclusion Criteria

• Alternative etiology for epilepsy.
• Already on another benzodiazepine.
• On a regularly scheduled opiate.
• Co-existing antibodies associated with seizures.
• Pregnancy or breast feeding.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
GAD65 Associated Epilepsy	Diazepam	Subjects diagnosed with GAD65 associated epilepsy, serum high-titer GAD65 positivity, trialed and failed at least 2 anti-seizure medications, at least 4 seizures per month will be started on diazepam.

Primary Outcome Measures

Name	Time	Method
Change in seizure frequency	Baseline, 3 months	Median percentage change in the mean monthly frequency of seizures as measured by patient recorded seizure frequency

Trial Locations

Locations (1)

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States